Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Neobiosis, LLC
WARNING LETTER
•Neobiosis, LLC•February 21, 2023

Neobiosis, LLC – FDA Warning Letter, Feb 21, 2023

Record Details

On June 5, 2024, the FDA issued a Warning Letter to Neobiosis, LLC, following an inspection from January 23 to February 21, 2023. The inspection revealed that Neobiosis manufactures and distributes unapproved drug and biological products derived from human amniotic fluid (Purified Amniotic Fluid - PAF) and umbilical cord (Wharton’s Jelly Cellular and Wharton’s Jelly Acellular) for allogeneic use.

The FDA determined these products are unapproved drugs and biological products because their intended uses, as evidenced by promotional materials (Facebook, YouTube, public interviews) for wound healing and orthopedic applications, classify them as such. They are not subject to an approved Biologics License Application (BLA) or an Investigational New Drug (IND) application. The umbilical cord products also fail to meet the homologous use and minimal manipulation criteria for HCT/Ps under 21 CFR 1271.10(a), thus requiring regulation as drugs and biological products.

Furthermore, the inspection identified significant Current Good Manufacturing Practice (CGMP) violations, rendering the products adulterated. Deficiencies include: - Failure to validate aseptic processes and sterilization for equipment (21 CFR 211.113(b)). - Inadequate environmental monitoring in aseptic processing areas (21 CFR 211.42(c)(10)(iv)). - Lack of

Company
Neobiosis, LLC
Inspection date
February 21, 2023
Product type
Biologics
Office
Division of Biological Products Operations I
Person
  • Michael W. Roosevelt (Program Division Director)
View Company Profile

ID · eeab0b82-3e99-4449-9d6f-d8af40e7968a

Violation Codes10
21 CFR 31221 CFR 1271.10(a)21 CFR 1271.3(c)21 CFR 1271.3(f)(1)21 CFR 1271.1521 CFR 211.113(b)21 CFR 211.42(c)(10)(iv)21 CFR 211.42(c)(10)(v)21 CFR 211.160(b)21 CFR 211.166(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Neobiosis, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.